SEC Filing Summary: Nile Therapeutics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nile Therapeutics, Inc. on April 22, 2011, covering events occurring on April 18, 2011. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements. Note: The request metadata references "Capricor Therapeutics, Inc.," but the filing text explicitly identifies the registrant as "Nile Therapeutics, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific executive compensation event and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the grant of a stock option award to Daron Evans, the Company's Chief Financial Officer. On April 18, 2011, the Compensation Committee awarded Mr. Evans a 10-year option to purchase 50,000 shares of common stock. The exercise price is set at $0.69 per share. The award is fully vested and immediately exercisable as of the grant date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document focuses solely on the terms of the stock option agreement under the Amended and Restated 2005 Stock Option Plan.
Key Facts for Investor Verification
- Confirm the registrant name is Nile Therapeutics, Inc., not Capricor Therapeutics, Inc.
- Verify the grant of 50,000 fully vested stock options to CFO Daron Evans at an exercise price of $0.69.
- Review the Amended and Restated 2005 Stock Option Plan referenced in the filing.
- Note that no financial performance data is included in this specific 8-K filing.